Nevirapine reduced mother-to-child transmission better than AZT--at 70 times less the cost.
A follow-up of a Uganda study shows that a single dose of nevirapine to the mother in labor and a single dose to the infant shortly after birth continues to show excellent results when the infants reach 18 months--despite breast feeding for 99% of the infants, and some HIV transmission that occurred as a result.